TrialJapanese journal of ophthalmology2021

Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.

Makoto Aihara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.